80 GUEST STREET, BOSTON, MA
Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Shareholder votes
Announces Appointment of Jeremy Bender, Ph.D., M.B.A., to Board of Directors
Reports First Quarter 2026 Financial Results and Business Highlights
Aura Biosciences, Inc. Enters Underwriting Agreement for Public Offering
Aura Biosciences Enters Stock Repurchase Agreement with Matrix Capital
Announces CEO Transition as Advances Phase 3 CoMpass Trial Toward Enrollment Completion
Q2
Q1
FY 2025
Q3
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Additional Securities
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Initial Statement of Beneficial Ownership